探讨巴曲酶治疗脑梗死急性期的临床效果

To Explore the Clinical Effect of Batroxobin on Acute Cerebral Infarction

目的研究分析巴曲酶（东菱迪芙）和降纤酶对急性期脑梗死患者的临床治疗效果。方法选取2009年3月～2010年2月我院80例急性脑梗死患者进行研究分析,将患者分组为对照组和观察组,各40例,对照组使用降纤酶治疗,观察组使用东菱迪芙治疗,比较分析其临床治疗情况。结果两组患者经过治疗后,观察组的临床治疗有效率是97.5%,对照组的临床治疗有效率是95.0%,其有效率不存在统计学差异性（P〉0.05）;观察组的纤维蛋白原组间和组内对比存在统计学差异性（P〈0.05）;此次研究无不良反应病例出现。结论急性期的脑梗死患者接受巴曲酶治疗的效果要比降纤酶治疗效果优秀,两组的治疗有效率差异性虽然比较小,但巴曲酶对患者的纤维蛋白原具有更好的降低效果。

Objective To study the batroxobin lnjection and defibrase on the clinical outcome in patients with acute cerebral infarction. Methods Selected 80 cases of patients with acute cerebral infarction from March 2009 to February 2010 in our hospital to carry on the research analysis, which were divided into the control group and the observation group, each group had 40 cases, the control group used defibrase to treatment, the observation group used batroxobin, comparative analysis of the clinical treatment situation. Results After treatment, the clinical efficacy of the observation group was 97.5%, the control group effective rate was 95%, the effective rate was not statistically different（P〉0.05）, the patients in the observation group were statistically different between the two groups（P〈0.05）, the study showed no adverse reaction. Conclusion The acute phase of cerebral infarction patients with batroxobin on effect than defibrase treatment effect is excellent, the effective rate of treatment group two the difference is relatively small, but batroxobin has better effect of reducing raw lnjection on fiber protein in patients, so the clinical recommended.